Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Gisèle Lacoste"'
Autor:
Christine Rotonda, Amélie Anota, Mariette Mercier, Bérangère Bastien, Gisèle Lacoste, Jean-Marc Limacher, Elisabeth Quoix, Franck Bonnetain
Publikováno v:
PLoS ONE, Vol 10, Iss 7, p e0132568 (2015)
This study describes the effect of TG4010 vaccine on Health related Quality of Life (HRQOL) in patients with stage IIIb and IV non-small-cell lung cancer (NSCLC).148 patients with advanced NSCLC expressing MUC1 were randomly assigned to receive TG401
Externí odkaz:
https://doaj.org/article/73c38d8026dc4016b86c3e6427605ff6
Autor:
Matthew S. Block, Jean-Pierre Delord, Christian H. Ottensmeier, Christophe Le Tourneau, Ana Lalanne, Olivier Lantz, Keith L. Knutson, Gisèle Lacoste, Annette Tavernaro, Maud Brandely, Nathalie Silvestre, Benoit Grellier, Yoshiko Yamashita, Onoue Kousuke, Naoko Yamagata, Eric Quemeneur, Kaidre Bendjama
Publikováno v:
Cancer Research. 82:CT182-CT182
Background: Cancer mutations acquired during carcinogenesis are not subject to central tolerance and thus, are cornerstone in cancer immunosurveillance. The use of mutation-derived neoepitopes to design cancer vaccines is an unprecedented opportunity
Autor:
Didier Debieuvre, Radj Gervais, Céline Halluard, A. Madroszyk, Enriqueta Felip, Christian H. Ottensmeier, Christos Chouaid, Andrzej Kazarnowicz, Frederic Forget, György Losonczy, Elisabeth Quoix, Annette Tavernaro, Aleksandra Szczesna, Z. Papai, Bérangère Bastien, J.T. Beck, Gisèle Lacoste, Jean Marc Limacher, Julien Adam, Virginie Westeel, Tania Palanché, Hervé Lena
Publikováno v:
The Lancet Oncology. 17:212-223
Summary Background MUC1 is a tumour-associated antigen expressed by many solid tumours, including non-small-cell lung cancer. TG4010 is a modified vaccinia Ankara expressing MUC1 and interleukin 2. In a previous study, TG4010 combined with chemothera
Autor:
Didier Debieuvre, Jean-Marc Limacher, Elisabeth Quoix, A. Madroszyk, Marc Buyse, Jean-Yves Bonnefoy, Z. Papai, Erich Stoelben, Gisèle Lacoste, Piotr Koralewski, Hervé Lena, Denis Braun, Alain Rivière, Marie-Pierre Chenard, Bérangère Bastien, Jean-Luc Breton, Annette Tavernaro, Rodryg Ramlau, Bruce Acres, Nadine Bizouarne, Virginie Westeel
Publikováno v:
Lancet Oncology
Lancet Oncology, Elsevier, 2011, 12 (12), pp.1125-1133. 〈10.1016/S1470-2045(11)70259-5〉
Lancet Oncology, Elsevier, 2011, 12 (12), pp.1125-1133. ⟨10.1016/S1470-2045(11)70259-5⟩
Lancet Oncology, Elsevier, 2011, 12 (12), pp.1125-1133. 〈10.1016/S1470-2045(11)70259-5〉
Lancet Oncology, Elsevier, 2011, 12 (12), pp.1125-1133. ⟨10.1016/S1470-2045(11)70259-5⟩
International audience; BACKGROUND: Chemotherapy is the standard of care for advanced stages of non-small-cell lung cancer (NSCLC). TG4010 is a targeted immunotherapy based on a poxvirus (modified vaccinia virus Ankara) that codes for MUC1 tumour-ass
Autor:
Philippe Slos, Christoph Rochlitz, Pascal Bleuzen, Pedro Romero, Jean-Marc Limacher, Bruce Acres, Mirjana Urosevic, Thierry Velu, Reinhard Dummer, Gisèle Lacoste
Publikováno v:
Molecular Therapy. 16(5):985-994
Numerous preclinical and clinical studies have shown that interleukin-2 (IL-2) induces regression of metastatic tumors. We have conducted a phase I/II, multicenter, open-label, dose-escalating study to evaluate the safety, efficacy, and biological ef
Autor:
Amélie Anota, Franck Bonnetain, Jean-Marc Limacher, Bérangère Bastien, Mariette Mercier, Christine Rotonda, Gisèle Lacoste, Elisabeth Quoix
Publikováno v:
PLoS ONE
PLoS ONE, Public Library of Science, 2015, 10 (7), pp.e0132568. ⟨10.1371/journal.pone.0132568⟩
PLoS ONE, Vol 10, Iss 7, p e0132568 (2015)
PLoS ONE, Public Library of Science, 2015, 10 (7), pp.e0132568. ⟨10.1371/journal.pone.0132568⟩
PLoS ONE, Vol 10, Iss 7, p e0132568 (2015)
International audience; Background: This study describes the effect of TG4010 vaccine on Health related Quality of Life (HRQOL) in patients with stage IIIb and IV non-small-cell lung cancer (NSCLC).Methods: 148 patients with advanced NSCLC expressing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc99b08df65c49416334b3aeb689ac20
https://hal.univ-lorraine.fr/hal-02944879
https://hal.univ-lorraine.fr/hal-02944879
Publikováno v:
Current Topics in Microbiology and Immunology ISBN: 9783319239095
Several approaches to antigen-specific immunotherapy of cancer antigen-specific immunotherapy of cancer have been tested clinically. In this chapter, we will describe studies done with the antigen MUC1. Tested MUC1 therapeutic vaccines include the fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0702fcde593668c91d92573a5acd0878
https://doi.org/10.1007/82_2015_429
https://doi.org/10.1007/82_2015_429
Autor:
Géraldine Honnet, Heiner Wedemeyer, Elisabeth Quoix, Elizabeth Calleja, Bérangère Marie-Bastien, Gisèle Lacoste, Isabelle Didillon, Francisco A.R. Garcia, Delphine Agathon, Jean-Marc Limacher, Pekka Nieminen
Publikováno v:
Cancer Research. 75:2498-2498
The modified vaccinia strain Ankara (MVA) is attenuated and non-propagative but retains infectivity and immunogenicity, its large DNA genome allows the insertion of several full-length coding sequences for disease associated antigens or other transge
Autor:
Aleksandra Szczesna, Zsolt Papai-Szekely, Christian H. Ottensmeier, Annette Tavernaro, Enriqueta Felip, Elisabeth Quoix, Frederic Forget, Bérangère Bastien, Jean-Marc Limacher, Gisèle Lacoste, John Nemunaitis, Lucio Crinò
Publikováno v:
Journal of Clinical Oncology. 33:3034-3034
3034 Background: TG4010 is an immunotherapy using an attenuated and modified poxvirus (MVA) coding for MUC1 and interleukin-2. A previous study showed that the baseline level of Triple Positive Act...
Autor:
Frederic Forget, Virginie Westeel, Bérangère Bastien, Céline Halluard, Radj Gervais, Z. Papai, Gisèle Lacoste, Christos Chouaid, Aleksandra Szczesna, E. Quoix, Andrzej Kazarnowicz, S. Marchand, K. Vanderheyde, Hervé Lena, Christian H. Ottensmeier, György Losonczy, J.T. Beck, Jean-Marc Limacher
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 90:S35